Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment. - Switching non-responders to aflibercept.

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•- Patients with neovascular age-related macular degeneration (AMD) that have shown inadequate response to anti-VEGF treatment, defined as a persistant central retinal thickness on optical coherence tomography (OCT) of >=300 µm combined with a response of no greater than a reduction of 50 µm after each previous intravitreal anti-VEGF treatment.;- Patients will have received at least 6 anti-VEGF injections within 1 year. ;- Active neovascular AMD seen as leakage on fluoresceine angiography and (sub-) retinal fluid on OCT. ;- Maximally 1 year since onset of visual complaints and start of anti-VEGF treatment. ;- Minimally 1 month and maximally 3 months between last anti-VEGF injection and first aflibercept injection. ;- Age 50 years and older;- Visual acuity at baseline between 20/25 and 20/320 (Snellen). ;- OCT available prior to first injection and after every three anti-VEGF injections.;- Give written informed consent.

•- Signs of subretinal fibrosis, scarring or geographic atrophy on OCT or FA, involving the center of the macula.;- Pigment epithelial detachment with a height of >=150µm. ;- Any ocular diseases beside AMD in the study eye, including myopic fundus and vitreoretinal traction. ;- Myopia of 8.00 D or more, irrespective of myopic fundus features. ;- Ocular surgery of the study eye <= 2 months prior to or during the previous anti-VEGF treatment.

发起方

niversitair Medisch Centrum Sint Radboud